Hepatitis B virus pre-genomic RNA and hepatitis B core-related antigen reductions at week 4 predict favourable hepatitis B surface antigen response upon long-term nucleos(t)ide analogue in chronic hepatitis B

• Published in: Clinical and molecular hepatology 2023-01, Vol.29 (1), p.146-162
• Main Authors: Mak, Lung-Yi, Wong, Danny, Kuchta, Alison, Hilfiker, Martina, Hamilton, Aaron, Chow, Ning, Mao, XianHua, Seto, Wai Kay, Yuen, Man-Fung
• Format: Article
• Language: English
• Subjects: Adult; Antigens; Antiviral Agents - therapeutic use; Biomarkers; chronic hepatitis b; Cloning; DNA, Viral; Female; Genomes; Genomics; Hepatitis B; hepatitis b core antigen; Hepatitis B Core Antigens; hepatitis b e antigen; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus - genetics; Hepatitis B, Chronic - diagnosis; Hepatitis B, Chronic - drug therapy; Humans; Liver; Male; Original; Polymerase chain reaction; RNA - therapeutic use; Statistical analysis; treatment outcome; viremia
• ISSN: 2287-2728; 2287-285X
• DOI: 10.3350/cmh.2022.0172

We investigated the dynamics of serum HBV pre-genomic RNA (pgRNA) and hepatitis B core-related antigen (HBcrAg) in patients receiving nucleos(t)ide analogues (NAs) and their predictability for favourable suppression of serum hepatitis B surface antigen (HBsAg). Serum viral biomarkers were measured at baseline, weeks 4, 12, 24, 36, and 48 of treatment. Patients were followed up thereafter and serum HBsAg level was measured at end of follow-up (EOFU). Favourable HBsAg response (FHR) was defined as ≤100 IU/mL or HBsAg seroclearance upon EOFU. Twenty-eight hepatitis B e antigen (HBeAg)-positive and 36 HBeAg-negative patients (median, 38.2 years old; 71.9% male) were recruited with median follow-up duration of 17.1 years (interquartile range, 12.8-18.2). For the entire cohort, 22/64 (34.4%) achieved FHR. For HBeAg-positive patients, serum HBV pgRNA decline at week 4 was significantly greater for patients with FHR compared to non-FHR (5.49 vs. 4.32 log copies/mL, respectively; P=0.016). The area under the receiver-operating-characteristic curve (AUROC) for week 4 HBV pgRNA reduction to predict FHR in HBeAg-positive patients was 0.825 (95% confidence interval [CI], 0.661-0.989). For HBeAg-negative patients, instead of increase in serum HBcrAg in non-FHR patients, FHR patients had median reduction in HBcrAg at week 4 (increment of 1.75 vs. reduction of 2.98 log U/mL; P=0.023). The AUROC for week 4 change of HBcrAg to predict FHR in HBeAg-negative patients was 0.789 (95% CI, 0.596-0.982). Early on-treatment changes of serum HBV pgRNA and HBcrAg at 4 weeks predict HBsAg seroclearance or ≤100 IU/mL in NA-treated CHB patients upon long-term FU.